Cynata Therapeutics Ltd
51S
Company Profile
Business description
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus manufacturing platform. There are currently three active clinical trials taking place using Cymerus technology, which are attempting to treat osteoarthritis and others.
Contact
100 Cubitt Street
Level 3
CremorneVIC3121
AUST: +61 370676940
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
2
Stocks News & Analysis
stocks
Undervalued ASX share with pathway to positive cash flow
Higher sales and a new loan facility increase our conviction.
stocks
Taiwan Semiconductor earnings: Buoyant guidance backed by voracious AI demand
We’ve raised our fair value estimate of Taiwan Semiconductor stock.
stocks
Ahead of earnings, is Netflix a buy, a sell, or fairly valued?
Watching sales growth and the potential for a major acquisition, here’s what we think of Netflix stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,221.20 | 37.00 | 0.40% |
| CAC 40 | 8,313.12 | 17.84 | -0.21% |
| DAX 40 | 25,352.39 | 66.15 | 0.26% |
| Dow JONES (US) | 49,442.44 | 292.81 | 0.60% |
| FTSE 100 | 10,238.94 | 54.59 | 0.54% |
| HKSE | 26,853.90 | 69.72 | -0.26% |
| NASDAQ | 23,530.02 | 58.27 | 0.25% |
| Nikkei 225 | 53,969.74 | 140.76 | -0.26% |
| NZX 50 Index | 13,717.38 | 57.59 | 0.42% |
| S&P 500 | 6,944.47 | 17.87 | 0.26% |
| S&P/ASX 200 | 8,897.90 | 36.20 | 0.41% |
| SSE Composite Index | 4,103.45 | 9.16 | -0.22% |